Adamis Submits New Drug Application to FDA for Its Epinephrine Pre-Filled Syringe

Adamis Submits New Drug Application to FDA for Its Epinephrine Pre-Filled 
SAN DIEGO, CA -- (Marketwired) -- 05/29/14 --  Adamis Pharmaceuticals
Corporation (NASDAQ: ADMP) today announced the submission of a New
Drug Application (NDA) to the U.S. Food and Drug Administration for
its epinephrine pre-filled single dose syringe (PFS) product.
Specifically the EPINEPHRINE INJECTION, USP, 1:1000 (0.3 mg
Pre-filled single dose syringe) is designed for the emergency
treatment of allergic reactions (Type I) including anaphylaxis.
Adamis submitted the NDA pursuant to Section 505(b)(2) of the Food
Drug & Cosmetic Act. 
Adamis' PFS provides a single dose of epinephrine (adrenaline), which
is considered the drug of choice for immediate administration in
acute anaphylactic reactions to insect stings or bites, allergic
reaction to foods (such as nuts), drugs and other allergens, as well
as idiopathic or exercised-induced anaphylaxis. Adamis' PFS is
designed to be the low-cost, easy-to-use therapeutic alternative to
existing epinephrine auto-injectors. 
Dr. Dennis Carlo, President and CEO of Adamis, stated, "We feel this
NDA submission represents a major milestone for Adamis. The
epinephrine market is large and growing and we estimate auto-injector
sales in the U.S. this year to approach one billion dollars. I
believe our PFS could be an affordable substitute for the costly
auto-injectors. These types of markets have proven to be cost
sensitive and we expect epinephrine to be no different. Our PFS could
allow Adamis to generate significant revenues and in time lead to
About Anaphylaxis
 Anaphylaxis is a serious, sometimes
life-threatening allergic reaction. The most common anaphylactic
reactions are to foods, insect stings, medications and latex.
According to information published by industry sources, up to 8% of
U.S. children under the age of 18 have a food allergy, and
approximately 38% of those with a food allergy have a history of
severe reactions. Anaphylaxis requires immediate medical treatment,
including an injection of epinephrine. The number of prescriptions
for epinephrine products has grown annually, as the risk of
anaphylaxis and allergic reactions have become more widely
understood. The company estimates that sales of prescription
epinephrine products in 2013 were at least $900 million, based on
industry data.  
About Adamis Pharmaceuticals Corporation
 Adamis Pharmaceuticals
Corporation is a specialty biopharmaceutical company focused on
developing and commercializing products in the therapeutic areas of
respiratory disease, allergy, oncology and immunology. The company's
current specialty pharmaceutical product candidates include the
Epinephrine Injection PFS syringe product for use in the emergency
treatment of anaphylaxis, APC-1000 and APC-5000 for the treatment of
asthma and chronic obstructive pulmonary disease, and APC-3000, an
HFA inhaled nasal steroid product for the treatment of allergic
rhinitis. The company's vaccine product candidates and cancer drug
product candidates under research and development include TeloB-VAX,
a cell-based therapeutic cancer vaccine and three drugs, APC-100,
APC-200, and APC-300, for the treatment of prostate cancer. 
Forward Looking Statements 
This press release may contain forward-looking statements that relate
to future events or our future results of operations or future
financial performance, including, but not limited to the following
statements: the ability to fund future product development and
business operations; future revenues expected from any of the
company's product candidates, assuming that they are developed and
approved for marketing by the FDA and other regulatory authorities;
the intellectual property protection that may be afforded by any
patents or patent applications relating to the company's technology;
uncertainties concerning the FDA approval process, including
uncertainties concerning whether the FDA will approve the company's
NDA relating to its PFS product and the timing of the FDA's
regulatory process; and the size of the market for prescription
epinephrine products or the company's PFS product and the absence of
any assurances concerning whether the size of that market or the rate
of prescriptions will increase or grow, or decrease, in the future.
Certain of these risks, uncertainties, and other factors are
described in greater detail in Adamis' filings from time to time with
the SEC, which Adamis strongly urges you to read and consider, all of
which are available free of charge on the SEC's web site at Except as required by law, Adamis expressly
disclaims any obligation to update any forward-looking statements.  
Adamis Contacts 
Mark Flather
Director, Investor Relations &
Corporate Communications
Adamis Pharmaceuticals Corporation
(858) 412-7951 
External Investor Relations 
Mark Gundy
(972) 240-1873 
Press spacebar to pause and continue. Press esc to stop.